Oncology Central

Cancer vaccines for hepatocellular carcinoma: future directions


Hepatocellular carcinoma (HCC) is the third and the fifth leading cause of death from cancer globally in men and women, respectively. The overall prognosis for HCC patients is poor, with a dismal 5-year survival rate of approximately 5–6%. The majority of patients are diagnosed when disease can be treated only with locoregional therapies resulting in limited survival benefits and tumor recurrence in 50–80% of patients at 5 years after treatment [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.